^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    danburstotug (IMC-001)

    i
    Other names: STIA1015, IMC001, STI 3031, STI A1015, STI3031, IMC-001, STI-3031, IMC 001, STI-A1015
    Associations

    News

    Trials
    Company:
    Immuneoncia Therap
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    DISTINKT: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, ImmuneOncia Therapeutics Inc. | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    5d
    A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (clinicaltrials.gov)
    P2, N=30, Recruiting, ImmuneOncia Therapeutics Inc. | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial primary completion date
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    TruSight Oncology 500 Assay
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    7d
    A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. (clinicaltrials.gov)
    P1, N=18, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase classification: P2 --> P1
    Phase classification
    |
    CRP (C-reactive protein)
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    9d
    A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. (clinicaltrials.gov)
    P2, N=18, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | N=30 --> 18 | Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: Jun 2026 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    5ms
    Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study (clinicaltrials.gov)
    P1, N=3, Terminated, Mayo Clinic | Trial completion date: Jan 2026 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Feb 2025; low/slow accrual
    Trial completion date • Trial termination • Trial primary completion date
    |
    danburstotug (IMC-001)
    8ms
    A Study Evaluating the Stability and Efficacy of IMC-001 for Injection on Atherosclerotic Plaques in Patients With ACS. (clinicaltrials.gov)
    P2, N=30, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | N=14 --> 30 | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    10ms
    A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (clinicaltrials.gov)
    P2, N=30, Recruiting, ImmuneOncia Therapeutics Inc. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Aug 2029 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    10ms
    A Study of IMC-001 on Improved Atherosclerotic Plaque Stability in Patients of ACS (clinicaltrials.gov)
    P2, N=14, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    1year
    NeoChance: Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Asan Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    danburstotug (IMC-001)
    1year
    A Study of IMC-001 on Improved Atherosclerotic Plaque Stability in Patients of ACS (clinicaltrials.gov)
    P2, N=14, Not yet recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    New P2 trial
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    over1year
    Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Mayo Clinic | N=40 --> 0 | Trial completion date: Nov 2025 --> Jul 2024 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2024 --> Jul 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    albumin-bound paclitaxel • danburstotug (IMC-001)
    2years
    A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, ImmuneOncia Therapeutics Inc.
    New P2 trial • Metastases
    |
    danburstotug (IMC-001)